EndoChoice Holdings Inc. (NYSE:GI), completed an IPO June 5, raising nearly $106 million on the New York Stock Exchange. River Cities Fund IV first invested in EndoChoice in 2008 and is the second-largest stakeholder in the company. Co-investors include Sequoia Capital, Council Ventures, Envest, Accelmed Fund and Evergreen Venture Partners. EndoChoice is a platform technology company that provides endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. Today, the Atlanta-based company has a global footprint with manufacturing in Germany, China and Atlanta with research and development in Israel. The company serves more than 2,500 customers in the US and works with distribution partners in 30 countries.